University of Oxford, Nuffield Department of Primary Care Health Sciences, Radcliffe Observatory Quarter, Oxford, United Kingdom.
University of Oxford, Nuffield Department of Medicine, Experimental Medicine Division, John Radcliffe Hospital, Oxford, United Kingdom.
PLoS One. 2018 Mar 28;13(3):e0194858. doi: 10.1371/journal.pone.0194858. eCollection 2018.
Our objective was to assess the clinical effectiveness of shorter versus longer duration antibiotics for treatment of bacterial infections in adults and children in secondary care settings, using the evidence from published systematic reviews. We conducted electronic searches in MEDLINE, Embase, Cochrane, and Cinahl. Our primary outcome was clinical resolution. The quality of included reviews was assessed using the AMSTAR criteria, and the quality of the evidence was rated using the GRADE criteria. We included 6 systematic reviews (n = 3,162). Four reviews were rated high quality, and two of moderate quality. In adults, there was no difference between shorter versus longer duration in clinical resolution rates for peritonitis (RR 1.03, 95% CI 0.98 to 1.09, I2 = 0%), ventilator-associated pneumonia (RR 0.93; 95% CI 0.81 to 1.08, I2 = 24%), or acute pyelonephritis and septic UTI (clinical failure: RR 1.00, 95% CI 0.46 to 2.18). The quality of the evidence was very low to moderate. In children, there was no difference in clinical resolution rates for pneumonia (RR 0.98, 95% CI 0.91 to 1.04, I2 = 48%), pyelonephritis (RR 0.95, 95% CI 0.88 to 1.04) and confirmed bacterial meningitis (RR 1.02, 95% CI 0.93 to 1.11, I2 = 0%). The quality of the evidence was low to moderate. In conclusion, there is currently a limited body of evidence to clearly assess the clinical benefits of shorter versus longer duration antibiotics in secondary care. High quality trials assessing strategies to shorten antibiotic treatment duration for bacterial infections in secondary care settings should now be a priority.
我们的目标是评估在二级保健环境中,使用已发表的系统评价证据,较短疗程与较长疗程抗生素治疗成人和儿童细菌感染的临床效果。我们在 MEDLINE、Embase、Cochrane 和 Cinahl 中进行了电子检索。我们的主要结局是临床缓解。使用 AMSTAR 标准评估纳入的综述质量,使用 GRADE 标准评估证据质量。我们纳入了 6 项系统评价(n = 3162)。4 项综述质量为高,2 项为中。在成人中,腹膜炎(RR 1.03,95%CI 0.98 至 1.09,I2 = 0%)、呼吸机相关性肺炎(RR 0.93;95%CI 0.81 至 1.08,I2 = 24%)或急性肾盂肾炎和败血症性尿路感染(临床失败:RR 1.00,95%CI 0.46 至 2.18)的临床缓解率方面,较短疗程与较长疗程之间无差异。证据质量为低至中。在儿童中,肺炎(RR 0.98,95%CI 0.91 至 1.04,I2 = 48%)、肾盂肾炎(RR 0.95,95%CI 0.88 至 1.04)和确诊细菌性脑膜炎(RR 1.02,95%CI 0.93 至 1.11,I2 = 0%)的临床缓解率方面,较短疗程与较长疗程之间无差异。证据质量为低至中。总之,目前评估二级保健中较短疗程与较长疗程抗生素的临床获益的证据有限。现在应优先进行高质量的试验,评估二级保健环境中缩短细菌感染抗生素治疗疗程的策略。